TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy

By sjmartinez • April 30, 2024

Bardia A, Pusztai L, Albain K, Ciruelos EM, Im SA, Hershman D, Kalinsky K, Isaacs C, Loirat D, Testa L, Tokunaga E, Wu J, Dry H, Barlow W, Kozarski R, Maxwell M, Harbeck N, Sharma P. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol. 2024 Apr 29;16:17588359241248336. doi: 10.1177/17588359241248336. PMID: 38686016; PMCID: PMC11057345.

Tags: adjuvant therapy, antibody–drug conjugates, Hematology/Oncology, immunotherapy, Programmed cell death ligand-1, Publications, triple-negative breast cancer, trophoblast cell-surface antigen 2

Oncofertility patterns after the overturn of Roe v. Wade

Baclig NV, Silverstein J, Shah V, Karlan B, Anand SR, Glaspy JA. Oncofertility patterns after the overturn of Roe v. Wade. J Natl Cancer Inst.[...]

Safety First

Moghanaki D, Gower A. Safety First. Int J Radiat Oncol Biol Phys. 2026 May 1;125(1):18. doi: 10.1016/j.ijrobp.2025.12.009. PMID: 42000358.

Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer

LeVee A, Hennessy MA, Idossa D, Leon-Ferre RA, Nanda R, McArthur H. Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer. Am Soc[...]